Quince Therapeutics, Inc.
163.0M
$5.70M
-1.42
$-1.31
No price alerts set. Add an alert to get notified!
-1.42
2.68
$-1.31
-188.51%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ADVM
Adverum Biotechnologies, Inc.
|
$4.36 | 0.00 | -0.50 | $96.26M | -1.60 |
|
ALXO
ALX Oncology Holdings Inc.
|
$1.91 | -6.37% | -1.02 | $103.70M | 0.20 |
|
ATYR
aTyr Pharma, Inc.
|
$0.74 | -2.14% | -0.97 | $72.09M | 0.18 |
|
CAMP
CAMP4 Therapeutics Corporation
|
$3.93 | -8.84% | -2.54 | $83.43M | 0.04 |
|
CNTB
Connect Biopharma Holdings Limited
|
$2.84 | -17.68% | -4.36 | $158.77M | 0.01 |
|
DTIL
Precision BioSciences, Inc.
|
$5.47 | -9.14% | -1.51 | $70.17M | 0.31 |
|
GUTS
Fractyl Health, Inc. Common Stock
|
$0.42 | -5.68% | -0.23 | $30.55M | 6.52 |
|
IFRX
InflaRx N.V.
|
$0.82 | -10.37% | -1.09 | $59.08M | 0.02 |
|
KLRS
Kalaris Therapeutics Inc
|
$5.32 | -1.39% | -2.80 | $99.40M | 0.02 |
|
MGX
Metagenomi, Inc. Common Stock
|
$1.27 | -4.17% | -0.54 | $47.59M | 0.26 |
* Peer stocks are selected based on market capitalization and sector
$4.55
$0.08
$0.00
0.00%
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
